|
1
|
Statistics and Information Department,
Ministry of Health, . Labour and Welfare: Vital Statistics. Tokyo:
2013
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mazur PK and Siveke JT: Genetically
engineered mouse models of pancreatic cancer: Unravelling tumour
biology and progressing translational oncology. Gut. 61:1488–1500.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dorado J, Lonardo E, Miranda-Lorenzo I and
Heeschen C: Pancreatic cancer stem cells: New insights and
perspectives. J Gastroenterol. 46:966–973. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen L: Co-inhibitory molecules of the
B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol.
4:336–347. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brahmer JR, Hammers H and Lipson EJ:
Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future
Oncol. 11:1307–1326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motzer RJ, Rini BI, McDermott DF, Redman
BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S,
Logan TF, et al: Nivolumab for metastatic renal cell carcinoma:
Results of a randomized phase II trial. J Clin Oncol. 33:1430–1437.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Hu W, Zheng X, Zhang C, Du P, Zheng
Z, Yang Y, Wu J, Ji M, Jiang J, et al: Emerging immune checkpoints
for cancer therapy. Acta Oncol. 54:1706–1713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Le Mercier I, Lines JL and Noelle RJ:
Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint
regulators. Front Immunol. 6:4182015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nomi T, Sho M, Akahori T, Hamada K, Kubo
A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al:
Clinical significance and therapeutic potential of the programmed
death-1 ligand/programmed death-1 pathway in human pancreatic
cancer. Clin Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okudaira K, Hokari R, Tsuzuki Y, Okada Y,
Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, et
al: Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a
mouse pancreatic cancer model. Int J Oncol. 35:741–749.
2009.PubMed/NCBI
|
|
17
|
Brahmer JR, Drake CG, Wollner I, Powderly
JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller
TL, et al: Phase I study of single-agent anti-programmed death-1
(MDX-1106) in refractory solid tumors: Safety, clinical activity,
pharmacodynamics, and immunologic correlates. J Clin Oncol.
28:3167–3175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Le DT, Lutz E, Uram JN, Sugar EA, Onners
B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al:
Evaluation of ipilimumab in combination with allogeneic pancreatic
tumor cells transfected with a GM-CSF gene in previously treated
pancreatic cancer. J Immunother. 36:382–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G,
Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al: Immunotherapy
converts nonimmunogenic pancreatic tumors into immunogenic foci of
immune regulation. Cancer Immunol Res. 2:616–631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang P, Su DM, Liang M and Fu J:
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1)
surface expression in breast cancer cells and promote
PD-L1-mediated T cell apoptosis. Mol Immunol. 45:1470–1476. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghebeh H, Lehe C, Barhoush E, Al-Romaih K,
Tulbah A, Al-Alwan M, Hendrayani SF, Manogaran P, Alaiya A,
Al-Tweigeri T, et al: Doxorubicin downregulates cell surface B7-H1
expression and upregulates its nuclear expression in breast cancer
cells: Role of B7-H1 as an anti-apoptotic molecule. Breast Cancer
Res. 12:R482010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gong W, Song Q, Lu X, Gong W, Zhao J, Min
P and Yi X: Paclitaxel induced B7-H1 expression in cancer cells via
the MAPK pathway. J Chemother. 23:295–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peng J, Hamanishi J, Matsumura N, Abiko K,
Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, et
al: Chemotherapy induces programmed cell death-ligand 1
overexpression via the nuclear factor-κB to foster an
immunosuppressive tumor microenvironment in ovarian cancer. Cancer
Res. 75:5034–5045. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Higashimura Y, Naito Y, Takagi T,
Mizushima K, Hirai Y, Harusato A, Ohnogi H, Yamaji R, Inui H,
Nakano Y, et al: Oligosaccharides from agar inhibit murine
intestinal inflammation through the induction of heme oxygenase-1
expression. J Gastroenterol. 48:897–909. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI,
Park YM, Oh S, Shin JG, Yao S, Chen L, et al: Interferon regulatory
factor-1 is prerequisite to the constitutive expression and
IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett.
580:755–762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mimura K, Kua LF, Shiraishi K, Kee Siang
L, Shabbir A, Komachi M, Suzuki Y, Nakano T, Yong WP, So J, et al:
Inhibition of mitogen-activated protein kinase pathway can induce
upregulation of human leukocyte antigen class I without
PD-L1-upregulation in contrast to interferon-γ treatment. Cancer
Sci. 105:1236–1244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee SK, Seo SH, Kim BS, Kim CD, Lee JH,
Kang JS, Maeng PJ and Lim JS: IFN-gamma regulates the expression of
B7-H1 in dermal fibroblast cells. J Dermatol Sci. 40:95–103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Isomura I, Shintani Y, Yasuda Y, Tsujimura
K and Morita A: Induction of regulatory dendritic cells by topical
application of NF-kappaB decoy oligodeoxynucleotides. Immunol Lett.
119:49–56. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qin X, Liu C, Zhou Y and Wang G: Cisplatin
induces programmed death-1-ligand 1(PD-L1) over-expression in
hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol.
Suppl 56:OL1366–OL1372. 2010.PubMed/NCBI
|
|
32
|
Maude SL, Frey N, Shaw PA, Aplenc R,
Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et
al: Chimeric antigen receptor T cells for sustained remissions in
leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bocci G, Danesi R, Di Paolo AD, Innocenti
F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G,
Conte PF, et al: Comparative pharmacokinetic analysis of
5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil
after conventional and reduced test dose in cancer patients. Clin
Cancer Res. 6:3032–3037. 2000.PubMed/NCBI
|
|
34
|
Kroep JR, Giaccone G, Voorn DA, Smit EF,
Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus
PE, Pinedo HM, et al: Gemcitabine and paclitaxel: Pharmacokinetic
and pharmacodynamic interactions in patients with non-small-cell
lung cancer. J Clin Oncol. 17:2190–2197. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sakai H, Kokura S, Ishikawa T, Tsuchiya R,
Okajima M, Matsuyama T, Adachi S, Katada K, Kamada K, Uchiyama K,
et al: Effects of anticancer agents on cell viability,
proliferative activity and cytokine production of peripheral blood
mononuclear cells. J Clin Biochem Nutr. 52:64–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Okino H, Maeyama R, Manabe T, Matsuda T
and Tanaka M: Trans-tissue, sustained release of gemcitabine from
photocured gelatin gel inhibits the growth of heterotopic human
pancreatic tumor in nude mice. Clin Cancer Res. 9:5786–5793.
2003.PubMed/NCBI
|
|
37
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Marzec M, Zhang Q, Goradia A, Raghunath
PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, et
al: Oncogenic kinase NPM/ALK induces through STAT3 expression of
immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci
USA. 105:20852–20857. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deer EL, González-Hernández J, Coursen JD,
Shea JE, Ngatia J, Scaife CL, Firpo MA and Mulvihill SJ: Phenotype
and genotype of pancreatic cancer cell lines. Pancreas. 39:425–435.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Awasthi N, Zhang C, Schwarz AM, Hinz S,
Wang C, Williams NS, Schwarz MA and Schwarz RE: Comparative
benefits of Nab-paclitaxel over gemcitabine or polysorbate-based
docetaxel in experimental pancreatic cancer. Carcinogenesis.
34:2361–2369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Holcomb B, Yip-Schneider MT, Matos JM,
Dixon J, Kennard J, Mahomed J, Shanmugam R, Sebolt-Leopold J and
Schmidt CM: Pancreatic cancer cell genetics and signaling response
to treatment correlate with efficacy of gemcitabine-based molecular
targeting strategies. J Gastrointest Surg. 12:288–296. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Adachi S, Kokura S, Okayama T, Ishikawa T,
Takagi T, Handa O, Naito Y and Yoshikawa T: Effect of hyperthermia
combined with gemcitabine on apoptotic cell death in cultured human
pancreatic cancer cell lines. Int J Hyperthermia. 25:210–219. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cao LP, Song JL, Yi XP and Li YX: Double
inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of
pancreatic cancer cells to gemcitabine. Oncol Rep. 29:1659–1665.
2013.PubMed/NCBI
|
|
45
|
Thoennissen NH, Iwanski GB, Doan NB,
Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, et al:
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT
pathway and potentiates antiproliferative effects of gemcitabine on
pancreatic cancer cells. Cancer Res. 69:5876–5884. 2009. View Article : Google Scholar : PubMed/NCBI
|
